Optimising the lipid-lowering pathway to help achieve LDL-C goals

Released 9 December 2025     Expires: 09 December 2027      Programme: Lipid-lowering 1 CPD/CME credit

Sponsorship Statement: This promotional e-learning module has been developed, organised, and funded by Sanofi, for UK healthcare professionals. Editorial support for this e-learning module has been provided by OmniaMed Communications. The media partners for this activity are The British Journal of Cardiology and Diabetes on the net. The British Journal of Cardiology and Diabetes on the net have had no input into the content of the activity.

Prescribing information and adverse event reporting information for Praluent® (alirocumab) is available here.

Adverse events should be reported. Reporting form and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to [email protected].


MAT-XU-2504705 (v1.0) | November 2025

Effective lipid management is crucial in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), yet many patients continue to fall short of their cholesterol target due to suboptimal treatment strategies.1 In this interactive e-learning module we’ll explore the key principles of lipid management, including current guidelines, low-density lipoprotein cholesterol (LDL-C) targets and pharmacological treatment options. We’ll also examine a patient-centred lipid-lowering pathway developed by Morecambe Bay NHS Trust, which uses a distance-to-goal approach to guide timely, appropriate escalation of treatment based on individual patient profiles and lipid targets.

Learning objectives

Upon completing this module, you should be able to:

  • Update your knowledge of national lipid guidelines and treatment targets
  • Assess lipid-lowering therapies and combination strategies, considering both treatment efficacy and individual patient needs
  • Implement practical, patient-centred strategies to support long-term lipid control and reduce cardiovascular risk across diverse patient groups

Accreditation

1 CPD/CME credit, 1 hours
BJC Learning has assigned one hour of CPD/CME credit to this module

Reference

1. Malick W et al. Eur J Prev Cardiol 2025;32(13);1136–44.

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

Register Now Already a member? Login now

One thought on “Optimising the lipid-lowering pathway to help achieve LDL-C goals”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.

back to top